Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates

Core Insights - Certara, Inc. reported quarterly earnings of $0.14 per share, exceeding the Zacks Consensus Estimate of $0.13 per share, and up from $0.10 per share a year ago, representing an earnings surprise of 7.69% [1] - The company posted revenues of $106 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.01%, and an increase from $96.65 million year-over-year [2] - Certara shares have increased approximately 22% since the beginning of the year, contrasting with a -3.3% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $103.7 million, and for the current fiscal year, it is $0.45 on revenues of $421.17 million [7] - The estimate revisions trend for Certara is mixed, leading to a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Certara belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]